Quote:

---

Trodelvy was approved for recurrent mTNBC (after failing two prior therapies), with a 529 patient randomized trial. It showed improvement in mPFS over a third line of chemo from 1.7 to 4.8 months.

---

The primary endpoint in that trial was median progression free survival and had a comparator arm of other drugs consisting of third line treatment. If you look at Erubilin's separate trial their mPFS was 4.1 months vs. the 4.8 for Trodelvy. A .7 month difference. In our study leronlimab's mPFS was 6.2 months a 1.4 month difference.

You make a big thing of different patient populations between the two trials but Trodelvy's trial excluded patients with brain metastasis. With the high rate of death in brain metastasis Gilead was using much healthier patients.